Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Trial of Inhaled SNSP113 in Adult Subjects with Cystic Fibrosis
2019-003178-25Phase 2Completed
- Sponsor
- Synspira Therapeutics
- Start
- Nov 2019
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cystic fibrosis (CF) comparing SNSP113 inhalation with Placebo inhalation (2 arms). Primary endpoint: Vital signs (blood pressure, heart rate, respiratory rate). Started Nov 2019; status: completed.
02
Drugs
poly (acetyl, arginyl) glucosamine
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2019-003178-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003178-25.